Scarica l'app Stockscreener
17.98
3.51%
0.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Precedente Chiudi:
$17.37
Aprire:
$17.41
Volume 24 ore:
1.35M
Relative Volume:
0.76
Capitalizzazione di mercato:
$2.64B
Reddito:
$340.81M
Utile/perdita netta:
$-419.65M
Rapporto P/E:
-6.3088
EPS:
-2.85
Flusso di cassa netto:
$-402.10M
1 W Prestazione:
-9.92%
1M Prestazione:
+2.63%
6M Prestazione:
+20.47%
1 anno Prestazione:
-23.39%
Intervallo 1D:
$17.24
$18.30
Intervallo di 1 settimana:
$17.20
$20.57
Portata 52W:
$10.57
$24.34
Denali Therapeutics Inc Stock (DNLI) Company Profile
Nome
Denali Therapeutics Inc
Settore
Industria
Telefono
(650) 866-8547
Indirizzo
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Confronta DNLI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
17.98 | 2.55B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2025-01-07 | Iniziato | Robert W. Baird | Outperform |
| 2025-01-03 | Iniziato | William Blair | Outperform |
| 2024-12-16 | Aggiornamento | Stifel | Hold → Buy |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Iniziato | B. Riley Securities | Buy |
| 2023-01-30 | Iniziato | SVB Securities | Outperform |
| 2022-12-05 | Iniziato | Cowen | Outperform |
| 2022-11-02 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-11-02 | Iniziato | BofA Securities | Buy |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-09-21 | Iniziato | Oppenheimer | Outperform |
| 2021-09-01 | Iniziato | SMBC Nikko | Outperform |
| 2021-05-18 | Iniziato | UBS | Buy |
| 2021-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-02-24 | Iniziato | Jefferies | Buy |
| 2020-02-19 | Iniziato | Stifel | Hold |
| 2020-01-27 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-26 | Iniziato | Wedbush | Neutral |
| 2019-09-13 | Iniziato | Nomura | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Iniziato | Janney | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Iniziato | Goldman | Neutral |
| 2018-01-02 | Iniziato | JP Morgan | Overweight |
| 2018-01-02 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Will Denali's Expanding Pipeline Deliver Breakthroughs In Neurodegenerative Medicine? - RTTNews
Wedbush Maintains 'Outperform' Rating for DNLI, Lowers Price Tar - GuruFocus
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
Denali Therapeutics dips after pricing $200M equity offering - MSN
Denali Therapeutics prices stock offering at $17.50 per share - MSN
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI) - Seeking Alpha
Denali Therapeutics (NASDAQ:DNLI) Shares Gap DownHere's What Happened - MarketBeat
Denali Therapeutics Prices $200 Million Public Offering - marketscreener.com
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - Sahm
Denali Therapeutics prices $200 million public offering By Investing.com - Investing.com India
Denali Therapeutics prices $200 million public offering - Investing.com
Denali Therapeutics says co prices public offering of 9.14 mln shares at $17.50 each - marketscreener.com
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50 - Stock Titan
Denali Therapeutics slides after launching $200 million share sale - TradingView — Track All Markets
Denali Therapeutics Plans $200 Million Public Offering - marketscreener.com
Denali Therapeutics stock falls after announcing $200 million public offering By Investing.com - Investing.com Australia
Denali Therapeutics stock falls after announcing $200 million public offering - Investing.com
Denali Therapeutics announces $200 million public offering By Investing.com - Investing.com India
Denali Therapeutics announces $200 million public offering - Investing.com
Denali Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Denali Therapeutics (NASDAQ: DNLI) plans $200M stock, pre-funded warrant sale with $30M option - Stock Titan
Marshall Wace LLP Sells 783,172 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Technical Reactions to DNLI Trends in Macro Strategies - news.stocktradersdaily.com
Denali enters into a $275M funding deal with Royalty Pharma - MSN
Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy - Indian Pharma Post
Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound - Yahoo Finance
Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) - Yahoo Finance
BTIG Research Reiterates Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - MarketBeat
3,947,387 Shares in Denali Therapeutics Inc. $DNLI Acquired by Norges Bank - MarketBeat
Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch By Investing.com - Investing.com South Africa
Denali Therapeutics (MUN:4DN) Price Target Decreased by 15.88% to 28.11 - Nasdaq
What's Going On With Denali Therapeutics Stock Friday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch - Investing.com Nigeria
Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating - marketscreener.com
FDA Pauses Denali’s Pompe Plans Due to Preclinical Safety Signals - BioSpace
BTIG Reiterates Denali Therapeutics (DNLI) Buy Recommendation - Nasdaq
William Blair Maintains Denali Therapeutics(DNLI.US) With Buy Rating - 富途牛牛
Schroder Investment Management Group Purchases 94,744 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com Australia
Transcript : Denali Therapeutics Inc.Analyst/Investor Day - MarketScreener
Denali Therapeutics and Royalty Pharma announce $275 million royalty funding agreement - marketscreener.com
Denali Therapeutics And Royalty Pharma Announce $275 Million Royalty Funding Agreement - TradingView
Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
Denali Therapeutics secures $275M royalty funding deal - MSN
Denali Therapeutics Secures $275M Royalty Funding Deal - TipRanks
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Therapeutics Inc Azioni (DNLI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):